May 9, 2023
Authored and Edited by Dr. Antje Brambrink; Maeve O'Flynn
On April 27, 2023, the European Commission (EU Commission) published its proposals for regulations on supplementary protection certificates (SPCs), including a unitary SPC for medicinal products and plant protection products (see here). This could be an incentive for the pharmaceutical industry to make use of the European patent with unitary effect (Unitary Patent), as it avoids the current split approach for product protection conferred by a Unitary Patent on one hand and various national SPCs on the other.
SPCs provide a patent term extension of up to five years for national parts of European patents protecting either medicinal products or plant protection products. The extension is provided to compensate the loss of effective patent protection caused by the lengthy testing required under European regulatory law to obtain marketing authorizations for such products.
SPCs are currently available on a national basis only, i.e. an innovator company that wants to extend its term of patent protection can apply for it on a country-by-country basis only. This is burdensome and costly since applications need to be filed e.g. in the various languages of the respective countries. Furthermore, the protection status may differ in the various jurisdictions, as each national authority makes its own decision. Ultimately this leads to a plurality of separate and independent rights.
There won’t be much change when the Unified Patent Court (UPC) opens for business on June 1, 2023. Although innovators may obtain European patents with unitary effect, they still have to apply for SPCs on a country-by-country basis to extend the protection conferred. As noted, this is not only burdensome and costly, but may also lead to a hotchpotch protection status if the national authorities decide differently. In addition, uniform protection will cease to exist when the protection conferred by the Unitary Patent expires.
Accordingly, the EU Commission has detected a clear need to
To achieve this the EU Commission proposes amendments of the already existing two regulations for SPCs related to (i) medicinal products for human and veterinary use (Regulation (EC) No 469/2009) and (ii) plant protection products (Regulation (EC) No 1610/96). The amendments include a new centralized procedure for the granting of national SPCs.
In addition, the EU Commission wants to establish two new EU regulations to provide also a Unitary SPC for both (i) medicinal products and (ii) plant protection products to complement the Unitary Patent, including also a centralized examination procedure.
But there is more. Also, a “Combined Application” is envisaged, where an applicant may request the grant of (i) a Unitary SPC if the product is protected by a Unitary Patent and (ii) of nationals SPCs for states not participating in the UPC.
Apart from that the currently known SPC regimen will remain unaffected, meaning that national SPCs are still available based on grants by national authorities.
For more information, visit our Insights:
Strategic Considerations for Opting in or out of the Unified Patent Court
Copyright © 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
May 9, 2024
Webinar
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.